Top Markets
Coin of the day
OmniAb, Inc. OmniAb, Inc.

OmniAb, Inc.

OABI
Clasificación en acciones #11864
OmniAb, Inc. is an American biotechnology firm focused on pioneering... OmniAb, Inc. is an American biotechnology firm focused on pioneering therapeutic antibody discovery. The company provides a sophisticated platform that allows its industry partners to access a broad spectrum of antibody repertoires and advanced screening techniques, thereby facilitating the development of next-generation treatments. Central to the OmniAb platform is the unique biological capability of proprietary genetically engineered animals, such as OmniRat, OmniChicken, and OmniMouse. These animals are modified to produce human-sequence antibodies, simplifying the creation of human therapeutic candidates. Additionally, OmniAb offers specialized technologies like OmniFlic (a transgenic rat) and OmniClic (a transgenic chicken), which address the requirements for bispecific antibody applications via a common light chain method, as well as OmniTaur, which leverages the distinct structural properties of cow antibodies for challenging targets. The company was founded in 2012 and is based in Emeryville, California.
Precio por acción
$4.48
Última sincronización: 2026-08-28
Capitalización bursátil
$649.33M
Cambio (1 día)
-2.84%
Cambio (1 año)
179.94%
País
US
Comercio OmniAb, Inc. (OABI)

Categoría

Ganancias de OmniAb, Inc. (OABI)
Ganancias en 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di OmniAb, Inc., gli utili attuali della società sono 0. Nel 2026, la società ha registrato un utile di 0, igual a agli utili del 2026, che erano di 0. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de OmniAb, Inc. desde 2026 hasta 2026
Ganancias al final de cada año
Año Ganancias Cambiar
Not enough data for the provided dates.
Ganancias de empresas similares o competidoras
Empresa Ganancias Diferencia de ganancias País
$5.27B -
US
$1.95B -
NL
$-4.02B -
AU
$-3.09B -
US
- -
CH